Pharma Executives Worried Over Presidential Candidates Demand for Drug Price Reform
Responding to tough talk by presidential candidates about price gouging by drug companies, pharmaceutical executives have told investors that they are working actively to influence the political debate. And in a move that reveals how much leeway drug firms actually have over pricing decisions, some are even saying that they have minimized price hikes in recent months to avoid attracting attention.
Democratic contenders Bernie Sanders and Hillary Clinton have both called for the government to do much more to bring down the price of medications. And last week, Republican candidate Donald Trump came out in support of allowing Medicare to negotiate for cheaper drug prices, a move that places him even to the left of some leaders in the Democratic Party.
The political environment has Wall Street worried. “We heard Bernie and Hillary last night go after drug pricing again and I think that's also something we are going to hear from the Republicans," warned Jami Rubin, the Goldman Sachs health care group analyst, on an earnings conference call last week for Johnson & Johnson.
Eli Lilly executive Jan Lundberg assured investors on his company's most recent earnings call that to combat the rhetoric around drug prices, the industry maintains “an active dialogue with each of the candidates" and will “work across party lines" to influence policy.
Merck chief executive Ken Frazier, speaking at the J.P. Morgan Health Care Conference in San Francisco last month, pledged to do more as chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA), the industry's lobbying group. “With respect to the political dynamic," Frazier said, “I think the most important thing, and I try to do this in my role as head of PhRMA, is I think the industry needs to communicate better with the outside world."
At the same conference, Biogen chief executive George Scangos, who also serves as co-chairman of PhRMA, said his firm increased prices on three drugs recently, but at a “somewhat lower number" to avoid placing “a target on our foreheads." He added that “it's still possible to take price increases" but that he thinks “it's wise to be a little prudent."
James Hammergren, the chief executive of McKesson, which is the largest wholesale drug distributor in the nation, echoed the call for the industry to hold off on price hikes to avoid attracting unwanted scrutiny. “I would say that political discourse that's taking place, and the congressional inquiries relative to pricing practices, I think are obviously going to have people at least pausing perhaps to consider whether now is the right time to take a price increase," Hammergren said during a recent earnings call. In 2012, the firm paid $151 million to settle claims the firm deliberately overcharged Medicaid for reimbursements for some 1,400 brand-name drugs.
Vijay Das, who is a health care policy advocate at the consumer group Public Citizen, says that the recent statements confirm that the pharmaceutical industry's “pricing decisions are based upon the reach of their market and political power, not development costs or lengthy FDA approval process." He notes that PhRMA spent $18 million lobbying the federal government in 2015 alone. Records maintained by the Center for Responsive Politics show that drugmakers across the board spent more than $235 million on lobbying last year.
John Maraganore, the chief executive of Alnylam Pharmaceuticals, told investors on the company's recent earnings call that recent talk of drug pricing is “political demagoguery that's going on right now." He conceded, however, later in the call that companies will need to “think about their growth based on productivity not based on arbitrary price increases."
Shkreli made worldwide headlines for dramatically hiking prices of the drugs he bought. Newly reported emails show that Shkreli boasted that by boosting the price of Daraprim, his company would bring in $375 million a year, “almost all of it profit."
But other firms have steadily increased prices as well. Vanda Pharmaceuticals, for instance, has increased the prices of its drug Hetlioz, which treats sleep disorders for the blind, by 76 percent since it was introduced in 2014. (You may have seen its new TV ads, featuring an Afghan war veteran.)
Pfizer, since the beginning of last month, has raised prices an average of 10.6 percent for more than 60 branded products. Bloomberg reports that prices have doubled over the last year for over 60 brand-name drugs.
Meanwhile, PhRMA has reportedly invested in a new marketing campaign to boost the image of the industry.
Reprinted with permission from The Intercept.
YOU MIGHT ALSO LIKE
- Construction Begins on Keystone XL Pipeline in Montana - EcoWatch ›
- Trump Approves Keystone XL Pipeline, Groups Vow 'The Fight Is ... ›
- Keystone XL Pipeline Construction to Forge Ahead During ... ›
EcoWatch Daily Newsletter
By Monir Ghaedi
As the COVID-19 pandemic continues to keep most of Europe on pause, the EU aims for a breakthrough in its space program. The continent is seeking more than just a self-sufficient space industry competitive with China and the U.S.; the industry must also fit into the European Green Deal.
European satellites continue to provide data on climate change.
In 2018, a team of researchers went to West Africa's Nimba Mountains in search of one critically endangered species of bat. Along the way, they ended up discovering another.
- Eek! Bat Populations Are Shrinking. Here Are A Few Ways to Help ... ›
- First Bat Removed From U.S. Endangered Species List Helps ... ›
- What We've Lost: The Species Declared Extinct in 2020 - EcoWatch ›
By Jim Palardy
As 2021 dawns, people, ecosystems, and wildlife worldwide are facing a panoply of environmental issues. In an effort to help experts and policymakers determine where they might focus research, a panel of 25 scientists and practitioners — including me — from around the globe held discussions in the fall to identify emerging issues that deserve increased attention.
Ask a Scientist: What Should the Biden Administration and Congress Do to Address the Climate Crisis?
By Elliott Negin
What a difference an election makes. Thanks to the Biden-Harris victory in November, the next administration is poised to make a 180-degree turn to again address the climate crisis.
- Biden Reaffirms Commitment to Rejoining Paris Agreement ... ›
- Joe Biden Appoints Climate Crisis Team - EcoWatch ›
- Biden Plans to Fight Climate Change in a New Way - EcoWatch ›